Prevention of vasospastic angina with nicardipine.

Abstract

Anti‐ischaemic effects and safety of nicardipine were assessed in 14 patients with vasospastic angina using a placebo comparison, cross‐over design study for 8‐13 weeks. The average daily dose of nicardipine for optimal angina prevention was 84 mg (range 40‐160 mg). Nicardipine administration, as compared with placebo, significantly reduced anginal frequency and nitroglycerin consumption during the single‐ and double‐ blind phases of the study. Nicardipine appears to be effective in the prevention of vasospastic angina and not to cause major adverse effects. 1985 The British Pharmacological Society